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NeuroprotectionAlongwith the increase in life expectancy over the last century comes the increased risk for development of age-
related disorders, including metabolic and neurodegenerative diseases such as Alzheimer's, Parkinson's and
Huntington's diseases. These chronic disorders share twomain characteristics: 1) neuronal loss inmotor, sensory
or cognitive systems, leading to cognitive and motor decline; and 2) a strong correlation between metabolic
changes and neurodegeneration. In order to treat them, a better understanding of their complexity is required:
it is necessary to interpret the neuronal damage in light of the metabolic changes, and to ﬁnd the disrupted
link between the peripheral organs governing energy metabolism and the CNS. This review is an attempt to
present ghrelin as part of molecular regulatory interface between energy metabolism, neuroendocrine and neu-
rodegenerative processes. Ghrelin takes part in lipid and glucose metabolism, in higher brain functions such as
sleep–wake state, learning andmemory consolidation; it inﬂuencesmitochondrial respiration and shows neuro-
protective effect. All these make ghrelin an attractive target for development of biomarkers or therapeutics for
prevention or treatment of disorders, in which cell protection and recruitment of new neurons or synapses are
needed.
© 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Ageing and related disorders
Improvements in life style and public health care have led to a signif-
icant increase in average lifespan over the last century (Vaupel, 2010).
Along with this comes increased risk for development of age-related
disorders including neurodegenerative diseases (NDD). Ageing is a
highly complex process determined by genetic and environmental fac-
tors. Changes in life style such as a moderate caloric restriction might
slow ageing, reduce age-related chronic diseases (Pitsikas and Algeri,
1992), improve some metabolic markers of ageing and even extend
the life span (Weindruch and Walford, 1988).
Brain ageing is accompanied by metabolic, morphological and neu-
rophysiological changes, particularly associated with impairments in
learning andmemory (Rosenzweig and Barnes, 2003). There are gender
differences in brain ageing e.g., brain atrophy starts earlier in men how-
ever, the progression is more rapid in women (Takeda and Matsuzawa,
1985). There is a loss of synapses, decrease in N-Methyl-D-aspartate
(NMDA) receptor responses, and alterations in calcium homeostasis
predominantly in regions essential to cognitive function (Fontán-
Lozano et al., 2007). Thus ageing impairs synaptic plasticity, which is a
basis for memory (Gruart et al., 2006), and changes the long-term
potentiation (LTP), regarded as a mechanism underlying learning
(Banks et al., 2014).
Chronic NDDwhich include Alzheimer's (AD), Parkinson's (PD), and
Huntington's (HD) diseases are progressive, associated with high mor-
bidity andmortality because, so far, there are very limited to no options
for their treatment. Although different, NDD share two important char-
acteristics: ﬁrst, systemic loss of neurons in motor, sensory or cognitive
systems (Martin, 1999) leading to cognitive andmotor decline; and sec-
ond, a correlation between metabolic changes and neurodegeneration
(Cai et al., 2012). The regenerative ability of neuronal tissue is limited
therefore, it is important to restrict neuronal impairment and death.
The processes inNDD are quite complex, and it is of primary signiﬁcance
to interpret the neuronal damage in light of themetabolic changes, and
to look for disrupted connection between the peripheral organs
governing the energy metabolism and CNS, i.e. for alterations in the
signalling molecules.
Ageing and the associated disorders involve perturbed energy
balance. Metabolism is regulated by both central inputs (mainly hypo-
thalamic) and peripheral signalling molecules such as insulin, ghrelin,
cholecystokinin, and adipokines (leptin, adiponectin, resistin). On the
other hand, one of those molecules — ghrelin, has also remarkably
wide and complex spectrum of effects on the neurons. Therefore, this
review is attempting to present ghrelin as a link between metabolism,
inﬂuenced by some life style aspects such as diets and sleep, and the
pathogenesis of neurodegeneration, and to emphasise on its potential
for creating biomarkers or therapeutics for management of metabolic
and NDD.Ghrelin
Synthesis and functions
Ghrelin is a 28-amino acid peptide, growth hormone (GH) secreta-
gogue (GHS) and appetite stimulator (Kojima et al., 1999). Ghrelin is pro-
duced mainly by gastric oxyntic cells (Date et al., 2000). They have no
contact with the glandular lumen; rather they are closely associated
with capillaries, suggesting an endocrine role of ghrelin (Camiña et al.,
2003). There is a second type of ghrelin-producing cells in the remainder
of the gastrointestinal tract (GIT) which are in contact with the intestinal
lumen (Sakata et al., 2002). These two types of cellsmay be distinctly reg-
ulated and play different physiological roles. Ghrelin production has also
been attributed to the pancreas (Date et al., 2002b; Wierup et al., 2002).Ghrelin has been detected within the brain: in neurons of the hypo-
thalamic arcuate nucleus (ARC) (Kojima et al., 1999), ventromedial hy-
pothalamic nucleus (VMN) and paraventricular nucleus (PVN) — areas
related to the control of GH-secretion and the appetite (Cowley et al.,
2003). Ghrelin-immunoreactive (IR) neurons have been observed in
the internuclear space between the lateral hypothalamus (LH), ARC,
PVN, VMN and dorsomedial nuclei and the third ventricle which high-
lights a different central role for ghrelin. Their location overlaps the
area with hypothalamic projections from the suprachiasmatic nucleus
(SCN), where the circadian clock resides and from the ventral lateral
geniculate body (Horvath, 1997, 1998). Thus, the central ghrelin expres-
sion determines a conjunction of the daily rhythms with visual stimuli
(Cowley et al., 2003) in accordance with ghrelin's meal-initiating effect
(Cummings et al., 2001).
Ghrelin-IR neurons have also been found outside the hypothalamus,
in the sensory-motor cortex and the cingulated gyrus (Hou et al., 2006).
In the primary sensory cortex they are much more in neonates than in
adult rats (Stoyanova, 2012; Stoyanova et al., 2009) suggesting a possi-
ble role during the early postnatal formation and remodeling of the
brain cortex.
Ghrelin gene encoded ﬁrst preproghrelin, which is cleaved to
proghrelin. Proghrelin is further cleaved to produce unacylated ghrelin
(des-acyl ghrelin or DAG) and acylated ghrelin (AG, C-ghrelin, or also re-
ferred to as ghrelin) (Hosoda et al., 2000). AG represents 10% of the total
circulating ghrelin (Ariyasu et al., 2001). It exerts central and peripheral
effects via GHS-receptor-1a (GHSR1a), a G protein-coupled receptor
(Kojima et al., 1999). AG binds to GHSR1a when caprylic (octanoylic)
acid is linked to serine by the enzyme ghrelin-O-acyltransferase
(GOAT) (Yang et al., 2008). The n-octanoyl group seems to be essential
for its binding and for some of AG effects (Van der Lely, 2009). AG has
metabolic and endocrine effects: induces food intake and accelerates
gastric emptying (Inhoff et al., 2008) via acetylcholine system (Date
et al., 2001). AG increases GH, prolactin, adrenocorticotropic hormone
(ACTH), and cortisol levels. It inhibits insulin and PP secretion and
increases plasma glucose levels (Kumar et al., 2010). These endocrine
actions are not mediated by the cholinergic system (Broglio et al.,
2003). AG levels are elevated in obesity and type 2 diabetes mellitus
(DM) (Rodriguez et al., 2009). Insulin-resistant obese subjects have
higher AG/DAG ratio, suggesting that AG excess can contribute to
obesity-associated insulin resistance (Barazzoni et al., 2007).
DAG is an unmodiﬁed (unacylated) form of ghrelin, dominant in the
plasma (90%) (Ariyasu et al., 2001). Until recently, DAGwas considered
as inactive because it does not bind to GHSR1a (Kojima et al., 1999).
However, DAG participates in many physiological and pathological pro-
cesses (Thompson et al., 2004), suggested to be considered as a separate
hormone, acting independently or together with AG (Broglio et al.,
2004; Delhanty et al., 2014). DAG is lower in obesity whereas AG levels
are unchanged indicating that DAG might be regulated by body weight
(Paciﬁco et al., 2009).
DAG induces negative energy balance increasing postprandial insu-
lin and decreasing AG, improves insulin sensitivity and decreases fat
mass (Asakawa et al., 2005; Benso et al., 2012). These effects are acute
and, at least partly, orchestrated in the hypothalamus (Martens et al.,
2010). In GHSR1a-deﬁcient mice DAG modulates the expression of
metabolically important genes (Delhanty et al., 2010). Administration
of GHSR1a-blockers antagonizes the AG effect on insulin secretion
whilst they do not affect DAG-induced insulin output which indicates
the existence of a speciﬁc DAG receptor (Gauna et al., 2006). The corre-
lation between DAG effect on postprandial glycaemia and the prepran-
dial AG levels makes DAG clinically relevant in subjects with relatively
high AG levels (Delhanty et al., 2012).
AG and DAG interact, and depending on the experimental setup,
DAG can either antagonize or support AG (Delhanty et al., 2012). Ad-
ministration of AG in GH-deﬁcient patients induces rapid rise in insulin
and glucose levels, reducing insulin sensitivity, whereas the combina-
tion of AG and DAG strongly improves insulin sensitivity (Gauna et al.,
74 I.I. Stoyanova / Neurobiology of Disease 72 (2014) 72–832004). AG suppresses PP secretion but it is counteracted by coadminis-
tration of DAG (Kumar et al., 2010). DAG together with AG diminishes
insulin and glucose response to AG, whilst DAG administration alone
had no effect (Broglio et al., 2004). These ﬁndings indicate that DAG
can be metabolically active by abrogating the effect of AG on insulin
secretion and glucose metabolism.
Secretion and associated disorders
Ghrelin secretion is regulated by nutritional and hormonal factors
(Rigamonti et al., 2002). Fasting and a low-protein diet increase
ghrelin-mRNA expression and plasma ghrelin, whilst there is a post-
prandial ghrelin decrease (Lee et al., 2002b). The temporal patterns
of ghrelin release are reciprocal to insulin but in a phase with leptin:
ghrelin and leptin decrease after meals (Cummings et al., 2001). Meals
inhibit secretion of both AG and DAG, whereas long-term fasting in-
hibits acylation but not total secretion (Lucidi et al., 2004). Acylation
may be regulated independently of secretion by nutrient availability in
the gut or by esterases cleaving the acyl group (Liu et al., 2008).
Sleep deprivation has been linked with increased ghrelin (Bodosi
et al., 2004). In healthy humans, total ghrelin shows an initial nocturnal
elevation and declining towards the morning (Spiegel et al., 2011). The
signiﬁcance of it remains unknown, and data providedby different stud-
ies are inconsistent. AG/DAG ratio is lower during sleep, suggesting that
GOAT activity may decrease during sleep. Thus, sleep has an inhibitory
effect on AG (Spiegel et al., 2011). The elevated nocturnal DAG could
be a result of increased vagal tone (Date et al., 2001). In night workers
and people with impaired sleep nocturnal ghrelin is increased but com-
bined with blunted postprandial suppression (Schiavo-Cardozo et al.,
2013). Nocturnal ghrelin increase is blunted in obese subjects (Dzaja
et al., 2004) but markedly elevated in anorexia nervosa (Müller et al.,
1995). However, a partial weight recovery brings it back to normal
(Otto et al., 2001) possibly because of ghrelin resistance in cachexia
(Camiña et al., 2003).
Somatostatin, leptin, insulin, insulin-like growth factor-I (IGF-I),
high-fat diet (Shimada et al., 2003) and obesity (Tschöp et al., 2001) in-
hibit ghrelin production. Because fasting ghrelin is negatively correlated
with insulin and leptin, the lowered ghrelin may be a consequence of
elevated insulin or leptin, a mechanism regarded as a physiological ad-
aptation to the positive energy balance of obesity (Ravussin et al., 2001).
Ghrelin is downregulatedwith ageing. In elderly healthy normal weight
people the values are as low as those in young obese, and signiﬁcantly
lower than those of young non-obese subjects (Rigamonti et al.,
2002). However, is this decrease due to ageing per se or is it a conse-
quence of age-related changes in other factors regulating ghrelin
synthesis and release, is not fully determined.
Ghrelin and gastrointestinal control and energy metabolism
Ghrelin has effects on food intake, gastrointestinal function and
energy. Food intake is controlled by a central homeostatic mechanism
triggered by satiety and starvation signals from the gut. Gut hormones
not only inﬂuence brain but also are expressed in there in concentra-
tions higher than those in the intestine (Dockray, 1976). This and the
widespread expression of their receptors by neurons raised theprospect
of cross-talk between gut and CNS. The effects of gut hormones on CNS
neurons are either direct ormediated by vagal afferents (Davison, 1986).
Several hormones, such as cholecystokinin, leptin, glucagon-like
peptide-1 (GLP-1), and peptide YY3–36, stimulate vagal afferents and ac-
tivate the pathway leading to inhibition of food intake and gastric emp-
tying (Dockray, 1988). However, there are other signalling molecules
with opposite (orexigenic) effect. Ghrelin (Date et al., 2002a; Kojima
et al., 1999), orexin-A (Burdyga et al., 2003) and endocannabinoids
(Gomez et al., 2002) stimulate feeding and accelerate gastric emptying.
Subdiaphragmatic vagotomy or capsaicin treatment completely abol-
ishes feeding and GH response to ghrelin, indicating that these effectsare mediated by the vagal nerve (Date, 2012). The interactions between
satiety and orexigenic signals are of signiﬁcance for the control of diges-
tion, therefore, their understanding is of great importance, particularly
in respect to the worldwide increase in obesity and for development of
potential non-invasive approaches for its treatment. The complexity of
the dialogue between the gut and the brain was presented in an elegant
way by Dockray (2014).
Ghrelin's orexigenic signals from the gut are transmitted to neurons
located in the ARC via the bloodstream (Hewson and Dickson, 2000) or
to the nucleus of the solitary tract (NTS) via the vagal afferents (Date,
2012). Within the ARC, there are orexigenic neurons expressing neuro-
peptide Y (NPY) and agouti-related protein (AgRP) (Hahn et al., 1998),
and anorexigenic neurons expressing pro-opiomelanocortin (POMC),
α-melanocyte stimulating hormone (α-MSH) and cocaine- and
amphetamine-regulated transcript (CART) (Andrews, 2011; Zheng
et al., 2003). AgRP was detected in 94% of NPY neurons (Hahn et al.,
1998) and their activation initiates feeding (Cummings et al., 2001).
The presence of GHSR1 in 94% of NPY neurons (Willesen et al., 1999)
alongwith the fact that 90% of NPY cells are activated by intraperitoneal
ghrelin application suggests a direct action of ghrelin on them (Wang
et al., 2002).
Whilst ghrelin directly stimulates orexigenic AgRP/NPY activity, it
indirectly inhibits anorexic POMC neurons via gamma-aminobutyric
acid (GABA) input from the same AgRP/NPY neurons (Cowley et al.,
2003). Deletion of vesicular GABA transporter in AgRP neurons elimi-
nates the inhibitory input onto the postsynaptic POMC neurons leading
to unopposed activation of themelanocortin systemand anorexia (Tong
et al., 2008). This GABA-mediated inhibition is accompanied by changes
in POMC synaptic plasticity. Ghrelin increases the number of inhibitory
synapses on POMC neurons, and thus elevates food intake by lowering
anorexigenic signals (Andrews et al., 2008).
Hypothalamic feeding regulation dependent on internal energy sta-
tus is referred to as homeostatic (Saper et al., 2002). However, there is
another, hedonic feeding, triggered by external factors such as visual
or olfactory food stimuli. Behavioural response to them involves the
orbitofrontal cortex, amygdala, and striatum (Rolls, 1994), a part of
themesolimbic system implicated in reward and motivated behaviours
(Cardinal et al., 2002). Intravenous ghrelin administration increases
neuronal response to food pictures, demonstrating that ghrelin also
favours food consumption by enhancing the hedonic and incentive
responses to food-related cues (Malik et al., 2008).
GIT function
Gastric acid secretion is regulated by central and peripheral path-
ways via endocrine, neurocrine, and paracrinemechanisms. The central
pathway is activated by sight, smell, taste and thought of food (Feldman
and Richardson, 1986), whilst the peripheral pathway is triggered by
mechanical and chemical stimuli (Lloyd and Debas, 1994). Most of the
neurotransmitters orchestrating feeding behaviour also participate
in the control of GIT function. Intraventricular ghrelin administration
stimulates gastric acid secretion, an effect completely abolished by
vagotomy or atropine administration (Date et al., 2001).
In addition to the peripheral ghrelin, there are hypothalamic
ghrelinergic neurons projecting to the dorsal vagal complex (DVC)
(Hou et al., 2006) which was also conﬁrmed by in vivo extracellular re-
cordings (Wang et al., 2007). Together with the expression of GHSR1
mRNA on the DVC neurons, it indicates that the effects of ghrelin on
GIT function are mediated via the vagal nerve (Date et al., 2001). This
may be physiologically relevant in preparing GIT to process food
(Masuda et al., 2000).
Energy metabolism
Ghrelin also regulates glucose and lipid metabolism. Treatment of
elderly or obese subjects with GHS induces hyperglycaemia and insulin
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secretion and glucose metabolism (Muller et al., 2001). Interestingly,
whilst intravenous administration of AG reduces insulin sensitivity,
the combination of AG plus DAG strongly improves it (Gauna et al.,
2004). AG targets the pancreatic islands directly and via a GH-
dependent pathway (Delhanty and Van der Lely, 2011). Unlike AG,
DAG induces negative energy balance (Asakawa et al., 2005). Peripheral-
ly administered DAG blocks the orexigenic effect of AG, improves insulin
sensitivity and reduces fat mass (Zhang et al., 2008). Thus both acylated
and nonacylated forms exert an acute and long-term control of glucose
metabolism and insulin sensitivity, which could be clinically relevant
(Van der Lely, 2009). AG increases adiposity GHSR1-independently
(Tschöp et al., 2000), and inhibits lipolysis (Muccioli et al., 2004). There-
fore, controlling AG/DAG ratio could help to regulate the balance
between adipogenesis and lipolysis, and to prevent development of
insulin resistance (Delhanty and Van der Lely, 2011).
The molecular mechanism of ghrelin activity links mitochondrial-
mediated effects of G-protein coupled receptors on neuronal functions
(Andrews, 2011). Ghrelin stimulates hypothalamic AMP-activated pro-
tein kinase (AMPK) (Andersson et al., 2004) which inhibits fatty acid
biosynthesis, reduces hypothalamic concentration of malonyl-CoA,
and consequently activates carnitine palmitoyltransferase-I (CPT1)
(López et al., 2008). Activation of AMPK–CPT1 axis improves mitochon-
drial respiration and reduces the generation of reactive oxygen species
(ROS) by uncoupling protein 2 (UCP2) which buffers excessive ROS
(Andrews et al., 2005, 2008). Thus, ghrelin not only controls central
and peripheral lipid metabolism (López et al., 2008), but via activation
of the AMPK–CPT1–UCP2 pathway ghrelin maintains the bioenergetics
capacity of AgRP/NPY neurons and increases their activity.
Ghrelin and higher brain functions
Ghrelin and sleep–wake state
The effects of ghrelin also concern the regulation of higher brain
functions including sleep–wake state (Steiger, 2007). GHSR1- or ghrel-
in-knockout (KO) mice lack or have attenuated arousal responses to
wake-inducing stimuli (Szentirmai et al., 2009). However, the effects
of exogenous ghrelin are still not completely clear. Ghrelin microinjec-
tions into LH, medial preoptic area or PVN prior to the rest in nocturnal
rodents increase wakefulness, motor activity and food intake, and sup-
press sleep. This “dark onset syndrome” occurs at the beginning of the
active period and evidently ghrelin triggers it (Szentirmai et al., 2007).
On the other hand, central administration of NPY (Szentirmai and
Krueger, 2006) and orexin (Hagan et al., 1999) has the same effect. Be-
cause ghrelin-, orexin- and NPYergic neurons form a network (Cowley
et al., 2003) with reciprocal interconnections, it could be speculated
that the wake-promoting effect of ghrelin is due to stimulation of
orexin- and NPYergic neurons (Szentirmai, 2012).
The effect on arousal differs between species and depends on the
way ghrelin is applied. In rats, both systemic and central ghrelin injec-
tions stimulate wakefulness and suppress rapid-eye-movement (REM)
and non-REM sleep (Szentirmai et al., 2007). In mice, intraventricular
administration increases wakefulness and suppresses REM and non-
REM sleep, and slow wave activity (SWA), whilst systemic ghrelin ad-
ministration solely stimulates feeding but does not affect sleep–wake
activity (Szentirmai, 2012). This could not be due to the fact that DAG
only crosses the blood–brain barrier (Yagi et al., 2013) because ARC de-
tects circulating ghrelin (Fry and Ferguson, 2010). These results indicate
that circulating and brain-derived ghrelin does not activate the same
central wake-promoting mechanism and the effects on wakefulness
and feeding are independent from each other.
The effect of systemic ghrelin or GHSR1-agonist administration on
sleep–wake activity is less consistent in the literature. In humans, the
effect depends on age, gender and time of administration. Ghrelin
does not modulate sleep in healthy women (Kluge et al., 2007b), butin depressed it diminishes the REM sleep (Steiger et al., 2011). In
contrast, early in the night ghrelin induces sleep in young men but
when injected at early morning there is no sleep-promoting effect and
EEG remains unchanged (Kluge et al., 2007a). After intravenous ghrelin
administration SWS and non-Rem sleep increase and wakefulness
decreases in healthy men, however in women sleep-EEG remains
unchanged (Kluge et al., 2007b, 2010). Since effects on sleep-EEG are
absent in both the pre- and postmenopausal women, it is unlikely that
estrogens contribute to this sexual dimorphism.
Ghrelin action during the night is dose-dependent: lower doses of
ghrelin promote sleep in men but not in women (Steiger et al., 2011).
Ghrelinmodulates the circadian system activity (Angeles-Castellanos
et al., 2004). GHSR1 is expressed in SCN master clock (Zigman et al.,
2006) and in brain regions activated in anticipation of scheduled
meals. Ghrelin acts as a non-photic stimulus which alters timing of
light-signalled behaviours and inhibits spontaneous locomotor activity.
Ghrelin-KO and GHSR1-KO show greater activity when exposed to light
for a long period (Lamont et al., 2014) which raises the question of how
ghrelin could cause it. It is important that GHSR1 is expressed in other
nuclei that are major inputs of the SCN master clock such as the
paraventricular nucleus of the thalamus (PVT), supraventricular zone,
dorsomedial nucleus of the hypothalamus (DMH) and LH. Therefore,
the absence of receptor in GHSR1-KO may alter the effect of ghrelin
on the outgoing signals from SCN (Leak and Moore, 2001). This hyper-
activity in GHSR1-KO suggests that other brain areas such as PVT, the
major circadian relay,may also be involved. Thus, the absence of ghrelin
action in the PVT could potentially change the normal inhibitory effects
of light on behaviour (Lamont et al., 2014). In GHSR1-KO the long-term
exposure to light disrupts the synchrony among the SCN clock cells
(Ohta et al., 2005) suggesting that there may be an interaction between
the effects of light and ghrelin that extends beyond a simple deﬁcit in
the ability of GHSR1-KO to entrain to scheduled feeding (Lamont
et al., 2014).Ghrelin and memory
The hippocampus, amygdala and dorsal raphe nucleus (DRN) are in-
volved in cognition. Ghrelin plays a role in it (Hansson et al., 2014) be-
cause their neurons express GHSR1 (Guan et al., 1997) and get activated
by central ghrelin administration (Carlini et al., 2002). Their activity is
considered as “high-order” feeding control because they are involved
in the learning and motivation aspects of feeding (Kanoski et al.,
2013). The dorsal hippocampus (DHPC) is associated with the control
of learning/memory related to visuospatial processing (Fanselow and
Dong, 2010), therefore ghrelin signalling in DHPC improves spatial
memory performance (Chen et al., 2011). The ventral hippocampus
(VHPC) is of importance in feeding and other appetitive/rewarding be-
haviours processing energy status-relevant neuroendocrine signals.
Thus, VHPC ghrelin signalling increases the ability of environmental
food-related cues to stimulatemeal initiation and enhances themotiva-
tion to obtain it (Kanoski et al., 2013).
Intraamygdala AG injection inﬂuences learning and short-term
memory, whilst the intra-hippocampal application improves the long-
term memory only. These effects are GHSR1 mediated (Tóth et al.,
2010). Ghrelin probably modulates speciﬁc intermediates involved in
memory acquisition/consolidation, but not retrieval (Carlini et al.,
2010) which could be related to serotonin (5-HT)-availability (Carlini
et al., 2007). Association between 5-HT and learning/memory has
been previously reported (Petkov and Kehayov, 1994), and 5-HT is
considered as a prerequisite to maintain control over the cognition
(Ghersi et al., 2011). Enhanced serotonin improves memory (Haider
et al., 2006), whereas 5-HT depletion impairs it (Evers et al., 2005).
Acute intraamygdala ghrelin administration increases activity of seroto-
ninergic neurons projecting to it, whilst GHSR1-KOdisplays a decreased
5-HT activity (Patterson et al., 2010).
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ghrelin injections increase spine density in the hippocampus (Berrout
and Isokawa, 2012), hypothalamus (Pinto et al., 2004) and the ventral
tegmental area, important for motivational aspects of multiple behav-
iours (Abizaid et al., 2006). When chronically applied to cortical neu-
rons, AG accelerates and prolongs synapse formation (Stoyanova et al.,
2013), leads to earlier onset of activity, and generates “mature” activity
pattern, and higher activity levels (Stoyanova and le Feber, 2014). These
ﬁndings complement the in vivo obtained evidence, that elevated ghrel-
in during fasting enhances synaptic function NMDA-dependently
(Fontán-Lozano et al., 2007). Ghrelin enhances memory task perfor-
mances (Diano et al., 2006) and promotes the long-term potentiation
(LTP) by elevation of nitric oxide synthase (NOS) activity (Carlini
et al., 2008).
Metabolism, neurodegeneration, and ghrelin
Alzheimer's disease
AD is the most common NDD (Hebert et al., 2003) causing cortical
and hippocampal neurodegeneration, which results in progressive cog-
nitive andmemory decline (West et al., 2000). Less than 1% of AD cases
are genetically determined, and develop symptoms before the age of 65
(Cai et al., 2012), whilst themajority of cases are referred to as sporadic.
Both forms express similar symptoms and pathophysiological mecha-
nisms which involve mitochondrial alterations, membrane-associated
oxidative stress, altered proteolytic processing of amyloid-beta (Aβ)
precursor protein (APP) and accumulation of neurotoxic forms of Aβ-
peptide (Mattson, 2004). The dynamics of AD biomarkers is very com-
plex, they develop independently and in parallel, rather than as a cas-
cade. The two major AD proteinopathies, Aβ and tau, might be
initiated independently in sporadic AD, and Aβ pathophysiology can ac-
celerate forerunning limbic and brainstem tauopathy (Jack et al., 2013).
Aβ and oxidative stress disrupt neuronal Ca2+, thereby rendering
neurons susceptive to excitotoxicity and the development of neuroﬁ-
brillary tangles (NFTs) composed of hyperphosphorylated microtubule
protein tau (Hardy et al., 1998). Memory deﬁcits in AD correlate with
the amount of Aβ deposited in the hippocampal neurons (Lefterov
et al., 2009). In this respect, ghrelin might be a preventive strategy for
amelioration of cognitive abilities because it has GHSR1-mediated
neuroprotective effect against Aβ oligomer-induced toxicity (Moon
et al., 2011). Ghrelin prevents ROS increase, calcium deregulation and
mitochondrial dysfunction (Gomes et al., 2014).
Obesity and diabetes mellitus (DM) are associated with increased
risk of developing dementia and AD (Moroz et al., 2008). DM shows
AD-type neurodegeneration, therefore, the sporadic AD regarded to be
as a brain type of DM has been suggested (Hoyer, 2002). Since insulin,
IGF-1, insulin-receptors, and the signalling mechanisms are impaired
in AD brain, this entity resembles DM and for that reason Steen et al.
(2005) proposed the term “Type 3 Diabetes”. However, DAG induces
negative energy balance (Asakawa et al., 2005), reduces fat mass
(Zhang et al., 2008) and improves insulin sensitivity and glucose
homeostasis (Delhanty et al., 2010), besides increasing β-cell mass,
function and survival (Granata et al., 2010). Thus, DAG shows a poten-
tial to prevent the diabetic-type of neurodegeneration in AD.
Additionally, DM causes diabetic encephalopathy manifested with
cognitive impairment (Gispen and Biessels, 2000). Its development is
multifactorial, involving both deﬁciency of brain-derived neurotrophic
factor (BDNF) and apoptosis (Ma et al., 2011). BDNF is the most preva-
lent growth factor in CNS (Barde et al., 1982), strong regulator of neuro-
nal development and synaptic plasticity, well known for its role in the
disease pathology (Autry and Monteggia, 2012). BDNF signals through
tropomyosin-related kinase B (TrkB) receptor, leading to activation of
three different intracellular pathways and augmentation of NMDA-
receptor currents (Levine et al., 1998). Each of these signallingpathways
confers unique function of BDNF on cells: phospholipase Cγ (PLCγ)pathway activates protein kinase C; phosphatidylinositol 3-kinase
(PI3K) activates serine/threonine kinase AKT; and mitogen-activated
protein kinase (MAPK) pathway activates several downstream effectors
(Mattson, 2008). Interestingly, ghrelin's effects are also based on, at
least partly, activation of these pathways (N. Wang et al., 2014; X.
Wang et al., 2014) which supports the idea that ghrelin and BDNF are
tightly linked together and to neuronal metabolism and plasticity, and
play a signiﬁcant role in maintaining normal memory function.
BDNF promotes neuronal differentiation and survival therefore
BDNF-deﬁciency may contribute to the impaired hippocampal
neurogenesis (Rossi et al., 2006) associated with diverse diseases in-
cluding AD (Nagahara et al., 2009). Indeed, there are lower levels of
BDNF in AD brain, suggesting a potential role for compromised neuro-
trophic support (Phillips et al., 1991). Neurogenesis is activity depen-
dent (Sendtner et al., 2000). As recently shown ghrelin leads to earlier
activity onset and higher activity levels (Stoyanova and le Feber,
2014). This local activation induces BDNF production in the postsynap-
tic neuron (Zafra et al., 1991) which upregulates genes encoding pro-
teins crucial for neuronal survival such as Bcl-2 (Mattson et al., 1995).
Neurogenesis involves NO production, which is Ca2+ mediated (Lee
et al., 2002a). On the other hand, central ghrelin administration
increases NO levels in the hypothalamus (Gaskin et al., 2003) therefore,
it could be speculated that ghrelin increases intracellular NO levels also
in the hippocampus responsible for the effects on memory retention
(Carlini et al., 2004).
BDNFmediates the effects of environmental factors on hippocampal
neurogenesis, learning andmemory. Hippocampal BDNF is increased in
response to physical activity (Oliff et al., 1998), dietary restrictions (Lee
et al., 2002b) and cognitive stimulation (Young et al., 1999) which
enhances synaptic plasticity, neurogenesis, learning and memory and
thus reduces the risk of AD (Mattson et al., 2004). BDNF is part of a cen-
tral mechanism integrating physical activity with elements of energy
metabolism to impact cognition therefore proper management of cellu-
lar energy is a vital requirement for synaptic function (Gomez-Pinilla
et al., 2008). BDNF is also implicated in the long-term potentiation and
synaptic plasticity (Figurov et al., 1996), as well as ghrelin (Diano
et al., 2006).
Apoptosis contributes to AD neuronal loss (Hroudová et al., 2014).
Caspases and Bcl families are important factors regulating apoptosis,
and mitochondria are implicated in a variety of key events during it
(Chan, 2004). Activation of caspase-3 is the major committed step of
apoptosis (Martin, 2001) however, AG inhibits it. AG targets the Bcl-2
family, inhibits the apoptotic cascade and favours cell survival (Zhang
et al., 2013). Ghrelin stabilizes mitochondria by reducing ROS produc-
tion, preserving mitochondrial inner transmembrane potential, and
preventing cytochrome-c release (Chung et al., 2007).
Oxidative stress and synaptic plasticity are interrelated such that an
imbalance in ROS formation inﬂuences synaptic plasticity and cognition.
Synaptic plasticity and molecules implicated in it such as BDNF are af-
fected by cellular energymetabolism (Wu et al., 2004). Hence, the inter-
action between oxidative stress and BDNF can be a fundamental
mechanism by which ageing affects neuronal plasticity (Cheng and
Mattson, 1994). Elevated ROS decrease BDNF expression and synaptic
plasticity (Wu et al., 2004) therefore ghrelin with its ability to increase
fatty acid oxidation and to buffer ROS can stimulate BDNF production
and preserve synapses. These ﬁndings also suggest that impairments
in ghrelin signalling may contribute to AD pathophysiology (Giordano
et al., 2007) and conversely, ghrelin has a potential for treating neuronal
damage and cognitive dysfunction (Atcha et al., 2009).
Ghrelin is affected by ageing (Rigamonti et al., 2002) and inhibition
of ghrelin signalling results in decreased number of spine synapses in
the striatum, followed by impaired performance in memory testing,
both of which have rapidly recovered by ghrelin administration (Levi
et al., 1990). On the other hand, AD impacts on the ghrelin system at
all levels (Gahete et al., 2010). The temporal cortex, which is one of
the most important structures for memory and cognition, is also one
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ghrelin, GOAT and GHSR1a are highly expressed in the temporal lobe
(Castañeda et al., 2010). However, in AD there is a striking reduction
of all of them whereas the expression of GHSR1b is increased, suggest-
ing that these changes in ghrelin system could be involved in the pro-
gression of the disease (Gahete et al., 2014). Although plasma ghrelin
decreases with age (Rigamonti et al., 2002) AD patients might have a
further reduction in local ghrelin production. Since ghrelin levels in
the cerebrospinal ﬂuid of AD patients are unchanged (Proto et al.,
2006) it is possible that perturbed local ghrelin secretion may be more
relevant to the aetiology of the disease (Gahete et al., 2010).
AD is also associated with appetite alterations (Creyghton et al.,
2004), named “anorexia of ageing”, which is often responsible for the
reduced body weight (Morley, 1997). Age-related ghrelin decline
might, at least partly, explain the somatotrope dysregulation in older
subjects (Rigamonti et al., 2002). Ghrelin responds to changes in energy
balance, and its orexigenic effects are mediated by hypothalamic NPY,
therefore, the positive correlation between NPY and ghrelin in AD and
healthy individuals may reﬂect the relationship among peripheral and
central signals in the control of eating (Proto et al., 2006).
Parkinson's disease
PD has a prevalence of 2% among people over the age of 65 years
(Lees et al., 2009), characterised with motor and non-motor dysfunc-
tions. The classical motor symptoms are caused by a neuronal loss in
pars compacta of substantia nigra (SN) and depletion of dopamine
(DA) in the striatum (Martin, 1999). Themotor symptomsmanifest rel-
atively late, in stage III of the disease (Braak et al., 2004), after 70–80%
loss of striatal DA. The non-motor symptoms precede them and reﬂect
changes in the olfactory bulb and cortex, brainstem sleep regulatory
centres and DMNV, as a major source of parasympathetic innervation
of GIT. This suggests that the nigrostriatal DA pathway is not involved
in the pathogenesis of non-motor symptoms (Bayliss and Andrews,
2013).
Aetiology of PD is believed to involve an interaction between genetic
and environmental factors (Horowitz and Greenamyre, 2010). In 10%
PD is genetically determined whilst in the majority, it is sporadic and
of unknown aetiology (Goldman and Tanner, 1998). Mitochondrial
dysfunction, oxidative stress, and aggregates of synaptic proteins α-
synuclein and ubiquitin (Spillantini et al., 1997) called Lewy bodies
have been implicated in PD pathology (Martinez and Greenamyre,
2012). Exposure to environmental factors, such as pesticides, may
increase the risk to develop PD (Gorell et al., 1998) by causing mito-
chondrial dysfunction, particularly reductions in the activity of com-
plex I (Schapira et al., 1989) which enhances ROS formation
(Kushnareva et al., 2002). ATP depletion by itself does not account
for neurodegeneration, instead the damage results from oxidative
stress (Sherer et al., 2003b, 2007).
Oxidative damage from toxin exposure may explain, in part, α-
synuclein aggregation (Betarbet et al., 2000). In PD brain, α-synuclein
becomes oxidatively modiﬁed and insoluble (Giasson et al., 2000). On
the other hand, higherα-synuclein expression can itself cause oxidative
damage (Hsu et al., 2000) therefore antioxidants are currently discussed
as potential therapies for PD (Sherer et al., 2003a). It is noteworthy to
mention that ghrelin activates UCP2-dependent alterations in mito-
chondrial respiration (Andrews et al., 2005) and thus protects DA func-
tion. Additionally, ghrelin is reduced during the pre-motor stage of PD
which might increase DA neuron vulnerability and thus contribute to
disease progression (Andrews et al., 2009). Indeed, ghrelin-KO or
GHSR1-KO mice are more susceptible to DA neuron loss, suggesting
that abnormal ghrelin signalling may represent a predisposition for
nigrostriatal DA dysfunction (Cai et al., 2012). Furthermore, ghrelin ad-
ministration prevents MPTP-induced DA death, metalloproteinase-3
expression, microglial activation, and the subsequent release of TNF-
alpha, IL-1beta, and nitrite. These data suggest that ghrelin may act asa survival factor for DA neurons by deactivating microglia and preserv-
ing mitochondrial respiration which makes it a valuable therapeutic
agent for PD (Moon et al., 2009).
Another factor probably implicated in pathogenesis of PD is BDNF
because its levels are lower in SN (Murer et al., 2001) and conditional
deletion of BDNF reduces the number of DA neurons (Baquet et al.,
2005). Conversely, administration of BDNF attenuates the loss of DA
neurons (Hyman et al., 1991) which indicates that BDNF is required
for their normal development. Additionally, transplantation of modiﬁed
ﬁbroblasts expressing BDNF into either the striatum or the midbrain
attenuates induced DA neuron loss (Levivier et al., 1995), promotes
functional recovery from the lesions, and corrects behavioural deﬁcit
(Mattson, 2008). Noteworthy, caloric restriction elevates BDNF in
striatal neurons, diminishes DA depletion and improves functional
outcome (Maswood et al., 2004). Since the low-calorie diet stimulates
ghrelin secretion (Rigamonti et al., 2002) and, on the other hand, ghrel-
in stimulates BDNF production, the underlying mechanism for the
neuroprotective effect of BDNF in PD could be based on the interaction
between these two regulatory molecules.
The non-motor symptoms have a prevalence of 90% in PD
(Weintraub et al., 2008). They comprise loss of appetite andweight, gas-
trointestinal dysfunction, cognitive impairment, reduced sleep quality
and depression.
Weight loss in PD is accompanied by low plasma levels of leptin
(Fiszer et al., 2010). Whilst low leptin may reﬂect the decrease in
body fat (Evidente et al., 2001), the low ghrelin is less intuitive and
warrants further investigation. Nevertheless, it indicates that ghrelin se-
cretion is disrupted in PD. So far, ghrelin agonists have been successful
for treatment of cachexia in cancer patients (Neary et al., 2004), which
suggests that ghrelin or agonists could be beneﬁcial to the PD patients
as well.
A PD patient has dysglycaemia, abnormal glucose tolerance (Lipman
et al., 1974) and insulin signalling, though there is a debate regarding a
direct association between PD and type 2 DM (Sandyk, 1993). In DM
model there are low levels of insulin, associated with decreased
amounts of DA transporter-mRNA and tyrosine hydroxylase-mRNA in
SN (Figlewicz et al., 1996). Normally, insulin receptors are abundant in
SN, however PD patients display much lower number of them
(Figlewicz et al., 2003) and signiﬁcant insulin resistance (Morris et al.,
2008). In addition, postprandial ghrelin response is reduced in PD, and
it might qualify as a peripheral biomarker and be of diagnostic or
therapeutic value (Unger et al., 2011). Reduced ghrelin might increase
the vulnerability of DAc neurons and thus to contribute to the disease
progression (Andrews et al., 2009).
PD patients frequently exhibit impaired gastrointestinal motility in
all stages of the disease (Natale et al., 2008) resulting in delayed gastric
emptying (Marrinan et al., 2014). Its aetiology is multifactorial and re-
lated to Lewy bodies' deposition in the enteric nervous system and in
brain nuclei. The interactions in this brain–gut axis involve complex
synergy between neural and hormonal elements, including ghrelin,
and may be the key to understanding the pathogenesis of PD. As men-
tioned previously, GIT functions are regulated by ghrelin via the vagal
nerve. Surprisingly, the myenteric plexus of the stomach (Beach et al.,
2010) and the DMNV are two of the ﬁrst sites where Lewy bodies
occur (Unger et al., 2011). It is still unclear if the impaired postprandial
ghrelin response is related to a process in the stomach or reﬂects a
perturbed vagal gastric innervation due to PD-related neurodegenera-
tion in the DMNV. Hence, the impaired ghrelin excretion might be
used as a peripheral biomarker for early PD (Unger et al., 2011) and
ghrelin could be a novel therapeutic strategy to combat neurodegener-
ation, loss of appetite and body weight associated with PD (Andrews
et al., 2009).
Nearly all PD patients suffer from selective cognitive impairments
(Zgaljardic et al., 2004). Sufﬁcient severity of it to fulﬁl criteria for de-
mentia occurs in up to 80% of PD patients (Aarsland et al., 2003).
Established phenotype of PD dementia (PDD) or Lewy Body dementia
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ness, or sleep disorders (Candela et al., 2013). A relatively unique fea-
ture of PD is that mood disturbance is associated with a quantitative
worsening of cognitive deﬁcits, which suggests that a common mecha-
nism might underlie both (Tröster et al., 1995). Moreover, depression
may be a forerunner of dementia (Lieberman, 2006). The causative
mechanisms remain complex, since the symptoms reﬂect brainstem
and cortical pathology involving several neurotransmitters, including
DA, serotonin, norepinephrine, and acetylcholine (Modugno et al.,
2013). Basal forebrain cholinergic system degenerates early in PD and
worsenswith the appearance of dementia. Their dysfunctionmay result
from DA degeneration (Leverenz et al., 2009).
Ghrelin has neuroprotective and disease-modifying effect in PD
(Bayliss and Andrews, 2013). It promotes and protects normal DA func-
tion (Schapira et al., 2014), enhances both learning andmemory via im-
proved synaptic plasticity, and has a neurogenic capacity (Moon et al.,
2014). Therefore, it may be a promising therapeutic agent for treatment
of cognitive decline in PD.
The majority of patients with PD suffer from sleep disturbances in-
cluding insomnia and daytime sleepiness (Ondo, 2014). Several studies
have identiﬁed a group of DA neurons in the ventral periaqueductal
grey matter (vPAG) (Freeman et al., 2001; Saper and Petito, 1982)
which appears to be critical for maintenance of sleep–wake behaviour.
Approximately 50% of them express c-Fos during wakefulness, but
none of them during sleep. They have connections with forebrain and
brainstem areas involved in control of arousal, with prefrontal cortex
(Yoshida et al., 1989), midline and intralaminar thalamus (Takada
et al., 1990), and the amygdala (Hasue and Shammah-Lagnado, 2002).
Dopamine transporter (Freeman et al., 2001) and receptors (Lewis
and O'Donnell, 2000) are present in both the thalamus and the cerebral
cortex, suggesting that DA can directly inﬂuence thalamo-cortical activ-
ity. Ventrolateral preoptic nucleus (VLPO) heavily innervates the lateral
PAG and the vPAG/dorsal raphe nucleus, but because VLPO neurons are
sleep-active and contain GABA, they inhibit the wake-active DA neu-
rons, promoting sleep (Sherin et al., 1998). This mutually inhibitory
circuitry is a component of the ﬂip-ﬂop switch for sleep/wake control
(Saper et al., 2005). Depletion of those DRN/vPAG DA neurons may
contribute to the excessive daytime sleepiness in PD (Lu et al., 2006).
REM-sleep behaviour disorder (RBD)develops in approximately 35–
50% of patients with older-onset PD in the pre-motor stages of the dis-
ease. RBD is characterised by dysfunction of systems that produce the
normal REM atonia of sleep (Schenck and Mahowald, 2002) and is
caused by synucleinopathies (Romenets et al., 2012). Patients with
RBD show increased cognitive impairment (Vendette et al., 2007) and
a risk of dementia (Postuma et al., 2012). In this regard, the long latency
from RBD expression to development of deﬁne disease provides a great
opportunity to intervene early when protective treatment might be
most effective. RBD and early stage PD patients exhibit reduced circulat-
ing ghrelin and postprandial ghrelin response. Since ghrelin possesses
protective effect on DAergic neurons, the reduced postprandial ghrelin
could be a cause for the reduced ghrelin-mediated neuroprotection,
and a long-standing increased vulnerability of DA neurons (Unger
et al., 2011). On the other hand, in RBD DMNV is affected, whilst SN is
not (Kim et al., 2010), suggesting postprandial ghrelin as another candi-
date for biomarker in early PD.
Huntington's disease
HD is one of themost common inherited NDDmanifested by contin-
uous involuntary movements, cognitive and psychiatric symptoms, and
autonomic dysfunctions (Landles and Bates, 2004). HD patients also ex-
hibit progressive weight loss, poor glycaemic control (Aziz et al., 2007)
and disturbed sleep (Taylor and Bramble, 1997). HD is caused by muta-
tion in gene encoding huntingtin (htt) protein (Andrew et al., 1993).
Processing of themutation is impaired causing intracellular aggregation
in striatal, brainstem and cortical neurons (Bates, 2003), combinedwitha loss of wild-type htt function (Cattaneo et al., 2001). However, neither
the normal function of htt nor the basis for such selective vulnerability is
fully understood, although several mechanisms such as impaired ener-
gymetabolism (Gu et al., 1996), excitotoxicity (Beal et al., 1986), oxida-
tive stress (Nakao and Brundin, 1997), mitochondrial dysfunction
(Brouillet et al., 1995) and apoptosis (Portera-Cailliau et al., 1995)
have been considered. All these processes may be interrelated because
they involve perturb calcium homeostasis (Petersén et al., 2000)
which leads to activation of a cascade of reactions such as induction of
non-speciﬁc permeabilization of the inner mitochondrial membrane
(Gunter and Pfeiffer, 1990), uncoupling respiration from ATP synthesis,
release of cytochrome-c, apoptosis inducing factor and pro-caspase
(Green and Reed, 1998). Calcium overload also activates different en-
zymes involved in cell death and increases ROS production (Reynolds
and Hastings, 1995).
HD is particularly interesting NDD because of involvement of neuro-
trophic factors,mainly the BDNF signalling (Lynch et al., 2007). Normal-
ly, htt up-regulates transcription of BDNF however, this activity is lost
when it becomes mutated, resulting in BDNF deﬁciency in the affected
brain regions (Ferrer et al., 2000) and death of striatal neurons. Con-
versely, restoring the normal htt activity increases BDNF production
which protects striatal neurons (Canals et al., 2004) and enhances
synaptic plasticity (Lynch et al., 2007). Furthermore, manipulations
increasing BDNF in the striatum and cortex, including environmental
enrichment (Spires et al., 2004), calorie restriction and antidepressant
treatment (Duan et al., 2004) forestall the neurodegenerative process.
Since ghrelin is one of the factors that serve as molecular interface
between metabolism, neuronal and cognitive functions, it could be
implicated into the neuroprotective effect of BDNF in HD.
HD is accompanied by considerable weight loss, particularly in the
ﬁnal stage (Kremer and Roos, 1992) however, it is not associated with
reduced food intake. On the contrary, HD patients demonstrate rather
increased appetite (Trejo et al., 2004). The higher energy expenditure
due to involuntary movements does not explain the lower bodyweight
in asymptomatic gene-carriers (Farrer and Yu, 1985) or in the early
stage of the disease, when the hipper activity is absent or minimal
(Djoussé et al., 2002). The striatum of HD patients expresses decreased
levels of full-length htt (Schilling et al., 1995) which precedes the
weight loss (Ona et al., 1999) and inﬂuences body weight in a dose-
dependentmanner (A. Aziz et al., 2008;N.A. Aziz et al., 2008). Reduction
of mutant huntingtin (mhtt) in the cortex partially improves motor and
mental deﬁcits but does not improve neurodegeneration, whereas re-
duction of mhtt in both cortical and striatal populations ameliorates
all behavioural deﬁcits and the selective brain atrophy. It reveals
interacting roles of cortical and striatal mhtt in HD pathogenesis, and
suggests that the optimal therapeutics have to target mhtt in both
neuronal populations (N. Wang et al., 2014; X. Wang et al., 2014).
The extremeweight loss in HDhas also been linked to selective neu-
ronal loss in the hypothalamic lateral tuberal nucleus (Djoussé et al.,
2002) and to alterations in the hypothalamic functions, leptin and
ghrelin levels (Petersén and Björkqvist, 2006). In HD, there is a signiﬁ-
cant reduction of OXA neurons in LH and disturbance in plasma ghrelin
and leptin (A. Aziz et al., 2008; N.A. Aziz et al., 2008). As ghrelin interacts
with OXAneurons (Solomon et al., 2007) andOXA suppresses GH secre-
tion (Seoane et al., 2004), the progressive loss of OXA neurons can also
account for the association between dysregulated GH and ghrelin secre-
tion in disease severity (Aziz et al., 2010b). Changes in ghrelin dynamics
in early stage of HD become more prominent with the progress of dis-
ease, whichmakes ghrelin a potential biomarker to assess it. Moreover,
decreased ghrelin could be correlated with the apoptotic processes
triggered by mhtt. Noteworthy that one of the earliest events in the
pre-symptomatic and early symptomatic stages is transcriptional up-
regulation of the caspase 1 gene (Ona et al., 1999). As the disease pro-
gresses, the caspase-3 gene get also up-regulated (Chen et al., 2000).
As described earlier in this review, ghrelin has the capacity to prevent
activation of these pathways (Andrews, 2011; Zhang et al., 2013) and
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with ghrelin could be beneﬁcial during the early stages of HDwhen the
activation of caspase pathway could be prevented and thus the progres-
sion of HD could be restricted.
HD is also characterised by night-time sleep impairment and circadi-
an rhythm disturbances with phase-shift in sleep/wake cycle towards
later hours (Aziz et al., 2010a)whichmay be related to pathologywithin
SCN molecular oscillation (Pallier et al., 2007). However, circadian
rhythm alterations rather than sleep impairment per se are related to
the cognitive deﬁcit in HD (Aziz et al., 2010a). Since ghrelin is able to
affect sleep–wake status and to modulate the circadian system activity
it could also be relevant for treatment of HD. However, the sexual di-
morphism in the reaction on ghrelin has to be taken into consideration
because after low doses of ghrelin sleep is promoted in male subjects
but remains unchanged in female individuals (Steiger et al., 2011).
Conclusions
Based on the currently available data, ghrelin seems to be much
more than a promoter of feeding and appetite. Ghrelin is involved not
only in lipid and glucose metabolism, but also in higher brain functions
such as sleep–wake state, learning and memory; it inﬂuences mito-
chondrial respiration and shows neuroprotective effect, takes part in
the etiopathogenesis of variety of neuroendocrine and NDD. All these
show that ghrelin is an important link betweenmetabolism and neuro-
degeneration and make it an attractive tool for development of bio-
markers or therapeutics for management of disorders, in which cell
protection and recruitment of new neurons or synapses are needed.
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